After carefully reading the December 2001 issue of the ARCHIVES, I feel it necessary to comment on the subject of dermoscopy, which was discussed in several articles.1-4 To be fair to the authors, my comments may be repetitious, as Menzies et al2 state, "One of the possible risks of monitoring involves noncompliance." Carli and colleagues4 further state, "In clinical practice, equivocal lesions are routinely excised to guarantee that an unrecognized melanoma will not be left untreated."
Schneider R. Dermoscopy in Melanoma Screening. Arch Dermatol. 2002;138(10):1378–1379. doi:10.1001/archderm.138.10.1378
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: